Mirum Pharmaceuticals Charts Ambitious Growth Strategy for 2024 and Future Expansion
- Mirum Pharmaceuticals forecasts global net product sales of $420 million to $435 million by 2025, driven by LIVMARLI.
- The company is advancing multiple clinical studies, including VISTAS and LIVMARLI EXPAND, focusing on rare diseases.
- Mirum plans a Phase 2 study for MRM-3379 in Fragile X Syndrome, expanding its rare disease portfolio further.
Mirum Pharmaceuticals Sets Ambitious Growth Path for 2024 and Beyond
Mirum Pharmaceuticals, Inc., based in Foster City, California, outlines its strategic vision for 2024, forecasting robust growth driven by product expansions and pivotal clinical developments. CEO Chris Peetz emphasizes the significance of this year as Mirum prepares to enhance its market position through key milestones. The company anticipates that global net product sales will reach between $420 million to $435 million in 2025, significantly bolstered by projected sales from LIVMARLI, which is expected to generate around $213 million in 2024. This growth trajectory reflects not only strong sales expectations but also an overall positive cash flow from operations.
The upcoming year features several critical milestones that could shape Mirum's future. Notably, the company is advancing its clinical pipeline with the completion of enrollment in the VISTAS study for volixibat in primary sclerosing cholangitis (PSC) by late 2025, and the VANTAGE study for primary biliary cholangitis (PBC) expected to commence in 2026. Additionally, Mirum is making strides with the LIVMARLI EXPAND Phase 3 study, targeting rare cholestatic conditions, which is also set to conclude by 2026. These studies not only underscore Mirum's commitment to addressing rare diseases but also align with its broader corporate strategy to expand its therapeutic offerings and market reach.
Furthermore, the U.S. Food and Drug Administration (FDA) has established a Prescription Drug User Fee Act (PDUFA) date of March 28, 2025, for the approval of chenodiol in treating cerebrotendinous xanthomatosis (CTX), indicating confidence in Mirum's innovative approaches. The company also plans to initiate a Phase 2 study for MRM-3379 in Fragile X Syndrome (FXS) in 2025, expanding its rare disease portfolio. Mirum's global footprint has extended to 30 countries, with successful reimbursement negotiations and launches in four major European markets, enhancing its position as a leader in the rare disease space.
In summary, Mirum Pharmaceuticals is poised for a transformative year with ambitious sales projections and significant clinical milestones. The company’s focus on expanding its product offerings and enhancing its global presence positions it favorably within the biopharmaceutical sector, particularly as it continues to navigate the complexities of rare diseases. As Mirum progresses through 2024, its efforts to secure further FDA designations and develop innovative therapies will be pivotal in establishing long-term growth and sustainability.